triphala churna cost

BEIJING (Reuters) – A COVID-19 vaccine candidate from China’s Walvax Biotechnology using mRNA technology triggered a stronger antibody response against the Omicron variant of the coronavirus as a booster dose than did Sinovac’s shot, clinical trial data showed.

The result for Walvax’s ARCoV candidate, which is yet to be peer reviewed, comes as competition for the COVID booster market intensifies in China, where more than half of the 1.4 billion population have so far received a non-mRNA booster shot.

Among 300 healthy adults previously vaccinated with two doses of either the Sinovac CoronaVac or Sinopharm BBIBP-CorV inactivated-virus vaccines around six months earlier, tamsulosin renal colic the neutralising antibody level against Omicron in those given an ARCoV booster was 4.4-fold higher than in those who received a Sinovac third dose, researchers said in a preprint published Tuesday on medRxiv.

“Most importantly,” the authors write, “83.75% of participants in the (ARCoV) booster group achieved the 1:8 threshold of neutralization antibody titers against the Omicron relative to that of only 35% of participants in the CoronaVac booster group.”

ARCoV is the most advanced Chinese COVID-19 mRNA candidate in terms of clinical trial progress. However, a large trial started last year has yet to generate efficacy data about how well it can reduce the risk of disease or death, raising investor concerns over whether and when the shot would be eventually approved for use.

The smaller booster trial did not test ARCoV in parallel with other vaccines that have also been reported to give a stronger antibody response than a third dose of the Sinopharm or Sinovac shot.

Aside from co-developing ARCoV with Suzhou Abogen Bioscience and the Academy of Military Medical Science, Walvax is partnering with Shanghai-based startup RNACure to work on a separate mRNA COVID-19 candidate.

Sinopharm and Sinovac are also testing their Omicron specific shots as potential boosters.

SOURCE: https://bit.ly/3zbgTQn medRxiv, online May 31, 2022.

Source: Read Full Article